Related Experiment Video
Updated: May 9, 2026

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Cancer decentralized clinical trials in the Veterans Health Administration
Daphne R Friedman1,2,3, Shannon L Elam2, Sarah Bloemers4
1National Oncology Program, US Department of Veterans Affairs, Washington, DC, United States.
Background:
Despite the importance of clinical trials in the advancement of cancer treatments, there are barriers to participant enrollment. Decentralized clinical trials are conducted at a different physical location than where patients receive medical care and can address patient-level and institution-level barriers that affect participant enrollment.
Methods:
The Veterans Health Administration (VA) created a cancer-focused decentralized clinical trial program with a dedicated research team, operational manual, and other standardized operational protocols to support trial conduct. The decentralized clinical trial program works closely with the VA Office of Research & Development and VA central institutional review board.
Results:
Ten cancer decentralized clinical trials have been implemented: 2 observational, 5 nontherapeutic interventional, and 3 therapeutic interventional. Eight were implemented as fully remote decentralized clinical trials, and 2 were hybrid decentralized clinical trials, with hybrid requiring collaboration with local clinicians for nonresearch activities. Across 47 VA medical centers, 134 Veterans enrolled: 31 (23%) in observational, 99 (74%) in nontherapeutic interventional, and 4 (3%) in therapeutic interventional decentralized clinical trials. Demographic characteristics of enrolled participants mirrored that of Veterans receiving cancer care through the VA's National TeleOncology service, including rurality (31%) and non-White minority status (19%). Examples of the methods for research conduct that have been used across these decentralized clinical trials are included.
Conclusions:
Cancer decentralized clinical trials can address barriers to participant enrollment, but not every clinical trial can be conducted in a decentralized manner. By sharing experiences regarding the conduct of cancer decentralized clinical trials in the VA, research sponsors, regulatory authorities, and other research groups can more readily and widely implement these trials.
More Related Videos
04:40Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
09:12Efficient Retroviral Transduction and Competitive Homing for Investigating GPCR-Mediated T-Cell Localization in Diverse Tissue Microenvironments
Published on: March 28, 2025
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...